EL7.AI
StocksMediumUpdated•Originally published 14 September 2026•Updated 14 September 2026•
1 min read

Beta Bionics Wins FDA Clearance for Mint Pump Amid Expanding Senseonics Partnership

Key Facts

1Senseonics and Beta Bionics announced a strategic partnership to integrate the one-year implantable CGM with the automated insulin delivery system.
2The commercial launch of the integrated system is planned for the fourth quarter of 2026.

In a development strengthening the position of wearable technology in the healthcare sector, Beta Bionics has secured FDA clearance for its Mint insulin patch pump. The new device features the advanced 3D Intelligence algorithm and full smartphone control capabilities, marking a strategic expansion of the company's product portfolio alongside its iLet Bionic Pancreas system integrated with Senseonics technology.

This regulatory milestone builds on the momentum of the recently announced partnership to integrate the Eversense 365 system—the world's first one-year implantable CGM—with Beta Bionics' automated delivery platforms. Per market data, Senseonics reported a robust 120% year-over-year increase in Q2 revenue to $14.5 million, reflecting growing demand for long-term diabetes solutions that minimize manual intervention.

Regarding price levels, SENS closed at $8.71 and BBNX at $16.57 (as of the September 11, 2026 close). Investors will now monitor the commercial rollout timeline for the Mint pump alongside the scheduled Q4 2026 launch of the integrated Eversense system, as economic calendar data indicates stable consumer spending patterns within the specialized healthcare industry.